Broad antibody claims under attack – USPTO issues memorandum raising written description requirements
Upon discovery of a novel biological target, an applicant may attempt to patent antibodies directed to the target, as such antibodies may have diagnostic and/or therapeutic applications. In the past, it has been possible to claim such antibodies in the US by merely stating that they are capable of binding the new biological target, and it was not necessary to characterise the structure or sequence of the antibody. Such an approach appears to be […]